Integrin α6β4 signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin

Min Chen; Brock Marrs; Lei Qi; Teresa Knifley; Heidi L. Weiss; John A. D’Orazio; Kathleen L. O’Connor

doi:10.3389/fonc.2022.1043538

Integrin α6β4 signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin

Min Chen, Brock Marrs, Lei Qi, Teresa Knifley, Heidi L. Weiss, John A. D’Orazio, Kathleen L. O’Connor

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Integrin α6β4 is highly expressed in triple negative breast cancer (TNBC) and drives its most aggressive traits; however, its impact on chemotherapeutic efficacy remains untested. We found that integrin α6β4 signaling promoted sensitivity to cisplatin and carboplatin but not to other chemotherapies tested. Mechanistic investigations revealed that integrin α6β4 stimulated the activation of ATM, p53, and 53BP1, which required the integrin β4 signaling domain. Genetic manipulation of gene expression demonstrated that mutant p53 cooperated with integrin α6β4 for cisplatin sensitivity and was necessary for downstream phosphorylation of 53BP1 and enhanced ATM activation. Additionally, we found that in response to cisplatin-induced DNA double strand break (DSB), integrin α6β4 suppressed the homologous recombination (HR) activity and enhanced non-homologous end joining (NHEJ) repair activity. Finally, we discovered that integrin α6β4 preferentially activated DNA-PK, facilitated DNA-PK-p53 and p53-53BP1 complex formation in response to cisplatin and required DNA-PK to enhance ATM, 53BP1 and p53 activation as well as cisplatin sensitivity. In summary, we discovered a novel function of integrin α6β4 in promoting cisplatin sensitivity in TNBC through DNA damage response pathway.

Original language	English
Article number	1043538
Journal	Frontiers in Oncology
Volume	12
DOIs	https://doi.org/10.3389/fonc.2022.1043538
State	Published - Nov 10 2022

Bibliographical note

Publisher Copyright:
Copyright © 2022 Chen, Marrs, Qi, Knifley, Weiss, D’Orazio and O’Connor.

Funding

This work was supported by the National Institutes of Health through National Cancer Institute (R01 CA223164-01 to KO’C, R21CA178753 to KO’C, and R01CA131075 to JD’O); the University of Kentucky Center for Cancer and Metabolism (P20GM121327) for providing imaging services and pilot funding (no number, to MC); by a Markey Women Strong Award through the Markey Cancer Foundation (no number, KO’C); and by the University of Kentucky Markey Cancer Center’s Support Grant (P30CA177558) to provide pilot funding (no number, to MC) and to enable services from the Markey Cancer Center Biospecimen Procurement and Translational Pathology, Biostatistics and Bioinformatics, and Flow Cytometry and Immune Monitoring Shared Resource Facilities.

Funders	Funder number
Markey Cancer Center Biospecimen Procurement and Translational Pathology, Biostatistics and Bioinformatics
Markey Cancer Center Foundation	KO’C
NIH-funded University of Kentucky Center for Cancer and Metabolism	P20GM121327
National Institutes of Health (NIH)	CA3164-01
National Childhood Cancer Registry – National Cancer Institute	R01CA131075, R21CA178753, R01 CA223164-01
Center for Information Technology
Center for Scientific Review
Office of Extramural Research, National Institutes of Health
University of Kentucky Markey Comprehensive Cancer Center	P30CA177558
Office of Research Infrastructure Programs, National Institutes of Health

Keywords

ATM
DNA-PK
cisplatin sensitivity
homologous recombination
integrin signaling
mutant p53
non-homologous end joining
triple negative breast cancer

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2022.1043538

Cite this

@article{77af04e398b9405c92b63ec832392706,

title = "Integrin α6β4 signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin",

abstract = "Integrin α6β4 is highly expressed in triple negative breast cancer (TNBC) and drives its most aggressive traits; however, its impact on chemotherapeutic efficacy remains untested. We found that integrin α6β4 signaling promoted sensitivity to cisplatin and carboplatin but not to other chemotherapies tested. Mechanistic investigations revealed that integrin α6β4 stimulated the activation of ATM, p53, and 53BP1, which required the integrin β4 signaling domain. Genetic manipulation of gene expression demonstrated that mutant p53 cooperated with integrin α6β4 for cisplatin sensitivity and was necessary for downstream phosphorylation of 53BP1 and enhanced ATM activation. Additionally, we found that in response to cisplatin-induced DNA double strand break (DSB), integrin α6β4 suppressed the homologous recombination (HR) activity and enhanced non-homologous end joining (NHEJ) repair activity. Finally, we discovered that integrin α6β4 preferentially activated DNA-PK, facilitated DNA-PK-p53 and p53-53BP1 complex formation in response to cisplatin and required DNA-PK to enhance ATM, 53BP1 and p53 activation as well as cisplatin sensitivity. In summary, we discovered a novel function of integrin α6β4 in promoting cisplatin sensitivity in TNBC through DNA damage response pathway.",

keywords = "ATM, DNA-PK, cisplatin sensitivity, homologous recombination, integrin signaling, mutant p53, non-homologous end joining, triple negative breast cancer",

author = "Min Chen and Brock Marrs and Lei Qi and Teresa Knifley and Weiss, \{Heidi L.\} and D{\textquoteright}Orazio, \{John A.\} and O{\textquoteright}Connor, \{Kathleen L.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 Chen, Marrs, Qi, Knifley, Weiss, D{\textquoteright}Orazio and O{\textquoteright}Connor.",

year = "2022",

month = nov,

day = "10",

doi = "10.3389/fonc.2022.1043538",

language = "English",

volume = "12",

}

TY - JOUR

T1 - Integrin α6β4 signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin

AU - Chen, Min

AU - Marrs, Brock

AU - Qi, Lei

AU - Knifley, Teresa

AU - Weiss, Heidi L.

AU - D’Orazio, John A.

AU - O’Connor, Kathleen L.

PY - 2022/11/10

Y1 - 2022/11/10

N2 - Integrin α6β4 is highly expressed in triple negative breast cancer (TNBC) and drives its most aggressive traits; however, its impact on chemotherapeutic efficacy remains untested. We found that integrin α6β4 signaling promoted sensitivity to cisplatin and carboplatin but not to other chemotherapies tested. Mechanistic investigations revealed that integrin α6β4 stimulated the activation of ATM, p53, and 53BP1, which required the integrin β4 signaling domain. Genetic manipulation of gene expression demonstrated that mutant p53 cooperated with integrin α6β4 for cisplatin sensitivity and was necessary for downstream phosphorylation of 53BP1 and enhanced ATM activation. Additionally, we found that in response to cisplatin-induced DNA double strand break (DSB), integrin α6β4 suppressed the homologous recombination (HR) activity and enhanced non-homologous end joining (NHEJ) repair activity. Finally, we discovered that integrin α6β4 preferentially activated DNA-PK, facilitated DNA-PK-p53 and p53-53BP1 complex formation in response to cisplatin and required DNA-PK to enhance ATM, 53BP1 and p53 activation as well as cisplatin sensitivity. In summary, we discovered a novel function of integrin α6β4 in promoting cisplatin sensitivity in TNBC through DNA damage response pathway.

AB - Integrin α6β4 is highly expressed in triple negative breast cancer (TNBC) and drives its most aggressive traits; however, its impact on chemotherapeutic efficacy remains untested. We found that integrin α6β4 signaling promoted sensitivity to cisplatin and carboplatin but not to other chemotherapies tested. Mechanistic investigations revealed that integrin α6β4 stimulated the activation of ATM, p53, and 53BP1, which required the integrin β4 signaling domain. Genetic manipulation of gene expression demonstrated that mutant p53 cooperated with integrin α6β4 for cisplatin sensitivity and was necessary for downstream phosphorylation of 53BP1 and enhanced ATM activation. Additionally, we found that in response to cisplatin-induced DNA double strand break (DSB), integrin α6β4 suppressed the homologous recombination (HR) activity and enhanced non-homologous end joining (NHEJ) repair activity. Finally, we discovered that integrin α6β4 preferentially activated DNA-PK, facilitated DNA-PK-p53 and p53-53BP1 complex formation in response to cisplatin and required DNA-PK to enhance ATM, 53BP1 and p53 activation as well as cisplatin sensitivity. In summary, we discovered a novel function of integrin α6β4 in promoting cisplatin sensitivity in TNBC through DNA damage response pathway.

KW - ATM

KW - DNA-PK

KW - cisplatin sensitivity

KW - homologous recombination

KW - integrin signaling

KW - mutant p53

KW - non-homologous end joining

KW - triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85142516482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142516482&partnerID=8YFLogxK

U2 - 10.3389/fonc.2022.1043538

DO - 10.3389/fonc.2022.1043538

M3 - Article

AN - SCOPUS:85142516482

SN - 2234-943X

VL - 12

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1043538

ER -

Integrin α6β4 signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this